Cue Biopharma Enters Material Definitive Agreement
Ticker: CUE · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1645460
Sentiment: neutral
Topics: material-agreement, corporate-action
TL;DR
Cue Biopharma signed a big deal, filing shows.
AI Summary
On September 26, 2024, Cue Biopharma, Inc. entered into a material definitive agreement. The filing also notes other events and includes financial statements and exhibits. The company was formerly known as Imagen Biopharma, Inc. until June 17, 2015.
Why It Matters
This filing indicates a significant new contract or partnership for Cue Biopharma, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks and opportunities, the specifics of which are not detailed in this initial filing.
Key Numbers
- 001-38327 — SEC File Number (Identifies the company's filing history with the SEC.)
- 47-3324577 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Cue Biopharma, Inc. (company) — Registrant
- Imagen Biopharma, Inc. (company) — Former Company Name
- September 26, 2024 (date) — Date of earliest event reported
- June 17, 2015 (date) — Date of name change from Imagen Biopharma, Inc.
- 40 Guest Street Boston, Massachusetts 02135 (location) — Principal executive offices address
FAQ
What is the nature of the material definitive agreement entered into by Cue Biopharma?
The filing does not specify the details of the material definitive agreement, only that one was entered into on September 26, 2024.
When did Cue Biopharma change its name from Imagen Biopharma, Inc.?
The company's name was changed from Imagen Biopharma, Inc. on June 17, 2015.
What is Cue Biopharma's principal executive office address?
Cue Biopharma's principal executive offices are located at 40 Guest Street, Boston, Massachusetts 02135.
What is the SEC file number for Cue Biopharma, Inc.?
The SEC file number for Cue Biopharma, Inc. is 001-38327.
What is the IRS Employer Identification Number for Cue Biopharma, Inc.?
The IRS Employer Identification Number for Cue Biopharma, Inc. is 47-3324577.
Filing Stats: 2,122 words · 8 min read · ~7 pages · Grade level 13.3 · Accepted 2024-09-27 16:17:01
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share CUE Nasdaq Capital Market
- $0 — Warrant at a combined offering price of $0.50, and each Pre-Funded Warrant is bein
- $0.47 — riting Agreement at a combined price of $0.47 and (ii) each Pre-Funded Warrant and ac
- $0.46906 — riting Agreement at a combined price of $0.46906. The Company estimates that the net p
- $10.7 m — from the offering will be approximately $10.7 million, after deducting underwriting dis
- $0.50 — nt will have an exercise price equal to $0.50. Each Common Stock Warrant will be exer
Filing Documents
- d856255d8k.htm (8-K) — 41KB
- d856255dex11.htm (EX-1.1) — 189KB
- d856255dex41.htm (EX-4.1) — 57KB
- d856255dex42.htm (EX-4.2) — 79KB
- d856255dex51.htm (EX-5.1) — 13KB
- d856255dex991.htm (EX-99.1) — 11KB
- g856255g0927121153692.jpg (GRAPHIC) — 2KB
- g856255g0927121321972.jpg (GRAPHIC) — 3KB
- g856255g0927153317974.jpg (GRAPHIC) — 5KB
- 0001193125-24-227977.txt ( ) — 628KB
- cue-20240926.xsd (EX-101.SCH) — 3KB
- cue-20240926_lab.xml (EX-101.LAB) — 17KB
- cue-20240926_pre.xml (EX-101.PRE) — 11KB
- d856255d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated September 26, 2024, by and between Cue Biopharma, Inc. and Oppenheimer & Co. Inc., as representative of the underwriters named therein 4.1 Form of Pre-Funded Warrant 4.2 Form of Common Stock Warrant 5.1 Opinion of Wilmer Cutler Pickering Hale and Dorr LLP 23.1 Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1) 99.1 Press Release dated September 26, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL) Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the expected closing of the public offering and the Company's cash runway. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "anticipate," "believe," "continue," "could," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "predict," "project," "seek," "should," "target," "will," "would" or other comparable terms, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the satisfaction of customary closing conditions related to the offering; the Company's limited operating history, limited cash and a history of losses; the Company's ability to achiev
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 27, 2024 CUE BIOPHARMA, INC. By: /s/ Daniel R. Passeri Name: Daniel R. Passeri Title: Chief Executive Officer